Nestle to buy Aimmune Therapeutics in $2.6B deal

Monday, 31. August 2020 08:04

Nestle S.A. revealed on Monday that Societes des Produits Nestle S.A. reached a deal to acquire United States-based biopharmaceutical company Aimmune Therapeutics Inc. in an all-cash transaction for $34.50 per share.

The fully-diluted equity value of the deal amounts to $2.6 billion. The agreement is expected to be finalized in the fourth fiscal quarter of 2020, upon completion of regulatory requirements.

"This transaction brings together Nestle's nutritional science leadership with one of the most innovative companies in food allergy treatment. Together, we will be able to create a world leader in food allergy prevention and treatment and offer a wide range of solutions that can transform the lives of people around the world living with food allergies," Nestle Health Science CEO Greg Behar noted in the press release.

Related Links: Nestlé SA
Author:
Breaking the News / MS